An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their ...
8d
IFLScience on MSNInhalable Cystic Fibrosis Gene Therapy 24 Years In The Making Enters Clinical TrialsA new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey towards seeing this treatment in the clinic. For this first phase, the aim ...
An inhaled gene therapy for cystic fibrosis developed by Boehringer Ingelheim is due to start clinical testing shortly, ...
2 CF is caused by mutations in the CFTR gene. These mutations cause the CFTR protein to become dysfunctional, which leads to the development of sticky, thick mucus clogging the airways, which causes ...
Cystic fibrosis (CF) is caused by defects in the CFTR gene, which causes a buildup of thick sticky mucus in the lungs and digestive system. It causes lung infections and gradually affects the ability ...
OXB announces that its proprietary lentiviral vector manufacturing technology will be used in Boehringer Ingelheim’s newly initiated LENTICLAIR ...
An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.
Get Instant Summarized Text (Gist) An inhalable gene therapy, BI 3720931, is being trialed in Europe to treat cystic fibrosis (CF) by inserting a functional CFTR gene into airway epithelial cells ...
A new inhalable medicine, potentially improving lung disease in all cystic fibrosis patients, is in human trials across the UK and Europe (1 Trusted Source A Study to Test How Well BI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results